Fluticasone Furoate 相關新聞

← 返回新聞總覽


Fluticasone Furoate 目前有 1 則相關新聞報導,預測適應症 20 個。

本頁整合 Fluticasone Furoate 的 AI 預測適應症與最新健康新聞,橘色標示的適應症表示近期有相關新聞報導。
藥物資訊
  • 原適應症:Asthma Indication Revinty Ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and...
  • 證據等級:L1
  • 預測適應症(20 個):
    • atopic eczema(100.0%)
    • allergic asthma(100.0%)
    • intrinsic asthma(100.0%)
    • bronchitis(99.9%)
    • asthma(99.9%)
    • 2-hydroxyethyl methacrylate sensitization(99.9%)
    • dermatitis, atopic(99.8%)
    • contact dermatitis(99.5%)
    • asthma-related traits, susceptibility to(99.4%)
    • occupational dermatitis(99.3%)
    • phototoxic dermatitis(99.1%)
    • obstructive lung disease(98.9%)
    • polyp of vocal cord(98.9%)
    • polyp of middle ear(98.9%)
    • fibroepithelial polyp(98.8%)
    • seborrheic dermatitis(98.8%)
    • neoplastic polyp(98.8%)
    • atopic dermatitis(98.8%)
    • polyp of vulva(98.8%)
    • polyp of frontal sinus(98.8%)

查看完整藥物報告 →

相關新聞(1 則)

Aktualisierte S2k-Leitlinie COPD 2026: Individualisierte Pharmakotherapie im Fokus - Gelbe Liste

2026-04-27 copd

來源:Gelbe Liste


免責聲明:本頁新聞由系統自動收集,僅供研究參考,不構成醫療建議。

Copyright © 2026 EuTxGNN Project. For research purposes only. Not medical advice.

This site uses Just the Docs, a documentation theme for Jekyll.